Breast Cancer: References

content provided by Healthwise

References

Citations

1. Beral V; Million Women Study Collaborators (2003). Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet, 362(9382): 419–427.

2. National Cancer Institute (2006). Probability of breast cancer in American women. National Cancer Institute Fact Sheet. Available online: http://www.cancer.gov/cancertopics/factsheet/Detection/probability-breast-cancer.

3. Tamimi RM, et al (2006). Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women. Archives of Internal Medicine, 166(14): 1483–1489.

4. American Cancer Society (2007). Breast Cancer Facts and Figures 2007. Atlanta: American Cancer Society. Available online: http://www.cancer.org/docroot/STT/stt_0.asp.

5. Dallal CM, et al. (2007). Long-term recreational physical activity and risk of invasive and in situ breast cancer. Archives of Internal Medicine, 167(4): 408–415.

6. Paley PJ (2001). Screening for the major malignancies affecting women: Current guidelines. American Journal of Obstetrics and Gynecology, 184(5): 1021–1030.

7. Gradishar WJ (2004). Male breast cancer. In JR Harris et al., eds., Diseases of the Breast, 3rd ed., pp. 983–990. Philadelphia: Lippincott Williams and Wilkins.

8. Women's Health Initiative Steering Committee (2004). Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA, 291(14): 1701–1712.

9. Armstrong K, et al. (2000). Assessing the risk of breast cancer. New England Journal of Medicine, 342(8): 564–570.

10. Willett WC et al. (2004). Nongenetic factors in the causation of breast cancer. In JR Harris et al., eds., Diseases of the Breast, 3rd ed., pp. 223–276. Philadelphia: Lippincott Williams and Wilkins.

11. Carey LA, et al (2006). Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA, 295(21): 2492–2502.

12. Thomas DB, et al. (2002). Randomized trial of breast self-examination in Shanghai: Final results. Journal of the National Cancer Institute, 94(19): 1445–1457.

13. Mahon SM (2003). Evidence-based practice: Recommendations for the early detection of breast cancer. Clinical Journal of Oncology Nursing, 7(6): 693–696.

14. Saslow D, et al. (2007). American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA: A Cancer Journal for Clinicians, 57(2): 75–89. Available online: http://www.caonline.amcancersoc.org/cgi/content/full/57/2/75.

15. Lehman CD, et al. (2007). MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. New England Journal of Medicine, 356(13): 1295–1303.

16. Veronesi U, et al. (2003). A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. New England Journal of Medicine, 349(6): 546–553.

17. Mansel RE, et al. (2006). Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: The ALMANAC trial. Journal of the National Cancer Institute, 98(9): 599–609.

18. Smith RA, D'Orsi CJ (2004). Screening for breast cancer. In JR Harris et al., eds., Diseases of the Breast, 3rd ed., pp. 103–130. Philadelphia: Lippincott Williams and Wilkins.

19. Martelli G, et al. (2005). A randomized trial comparing axillary dissection to no axillary dissection in older patients with T1N0 breast cancer: Results after 5 years of follow-up. Annals of Surgery, 242(1): 1–6.

20. Burstein HJ (2003). Breast cancer: Supportive measures and follow-up care. In B Furie et al., eds., Clinical Hematology and Oncology, pp. 763–768. Philadelphia: Churchill Livingstone.

21. Goss PE, et al. (2003). A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. New England Journal of Medicine, 349(19): 1793–1802.

22. Coombes RC, et al. (2004). A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. New England Journal of Medicine, 350(11): 1081–1092.

23. ATAC Trialists' Group (2005). Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet, 365(9453): 60–62.

24. Thurlimann B, et al. (2005). A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. New England Journal of Medicine, 353(26): 2747–2757.

25. Boccardo F, et al. (2007). Switching to an aromatase inhibitor provides mortality benefit in early breast carcinoma. Cancer, 109(6): 1060–1067.

26. Chlebowski T, et al. (2003). Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: The Women's Health Initiative randomized trial. JAMA, 289(24): 3243–3253.

27. Beral V, et al. (2002). Breast cancer and breastfeeding: Collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50,302 women with breast cancer and 96,973 women without disease. Lancet, 360(9328): 187–2218.

28. Prentice RL, et al. (2006). Low-fat dietary pattern and risk of invasive breast cancer. JAMA, 295(6): 629–642.

29. Taylor EF, et al. (2007). Meat consumption and risk of breast cancer in the U.K. women's cohort study. British Journal of Cancer, 96(7): 1139–1146.

30. Cho E, et al. (2006). Red meat intake and risk of breast cancer among premenopausal women. Archives of Internal Medicine, 166(20): 2253–2259.

31. McTiernan A, et al. (2004). Recreational physical activity and the risk of breast cancer in postmenopausal women. JAMA, 290(10): 1331–1336.

32. Vogel VG, et al. (2006). Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NASBP study of tamoxifen and raloxifene (STAR) P-2 trial. JAMA, 295(23): 2727–2741.

33. Abramowicz M (2006). Raloxifene (Evista) for breast cancer prevention in postmenopausal women. Medical Letter on Drugs and Therapeutics, 48(1234): 37.

34. Morrow M, Gradishar W (2002). Breast cancer. BMJ, 324(7334): 410–414.

35. Isaacs C, et al. (2004). Evaluation and management of women with a strong family history. In JR Harris et al., eds., Diseases of the Breast, 3rd ed., pp. 315–345. Philadelphia: Lippincott Williams and Wilkins.

36. Holmes MD, et al. (2005). Physical activity and survival after breast cancer diagnosis. JAMA, 293(20): 2479–2486.

37. Drouin JS, et al. (2006). Random control clinical trial on the effects of aerobic exercise training on erythocyte levels during radiation treatment for breast cancer. Cancer, 107(10): 2490–2495.

38. Ohira T, et al. (2006). Effect of weight training on quality of life in recent breast cancer survivors: The Weight Training for Breast Cancer Survivors (STBS) study. Cancer, 106(9): 2076–2083.

39. Collado-Hidalgo A, et al. (2006). Inflammatory biomarkers for persistent fatigue in breast cancer survivors. Clinical Cancer Research, 12(9): 2759–2766.

40. Kris MG, et al. (2006). American Society of Clinical Oncology guideline for antiemetics in oncology: Update 2006. Journal of Clinical Oncology, 24(18): 2932–2937.

41. National Cancer Institute (2006). Breast Cancer PDQ: Treatment–Health Professional Version. Available online: http://www.cancer.gov/cancertopics/pdq/treatment/breast/healthprofessional.

42. Harris EER, et al. (2006). Late cardiac mortality and morbidity in early-stage breast cancer patients after breast-conservation treatment. Journal of Clinical Oncology, 24(25): 4100–4106.

43. Hooning MJ, et al. (2007). Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. Journal of the National Cancer Institute, 99(5): 365–375.

E-mail This | Print This Previous Chapter | Next Chapter

Last updated:	August 31, 2007
Author:	Kathe Gallagher, MSW
Reviewed By:	Joy Melnikow, MD, MPH - Family Medicine, Douglas A. Stewart, MD - Medical Oncology
Editors:	Cynthia Tank, Pat Truman